News & Updates

Emodepside appears to be efficacious in the treatment of hookworm infections, with cure rates that surpass those achieved with albendazole but at the expense of increased adverse events (AEs), as shown in a phase IIb study.

First-line immunotherapy results in improved median overall survival (OS) in patients with advanced Merkel cell carcinoma (MCC), reports a study, noting a better performance than chemotherapy in the real-world setting.

Preoperative treatment with tofacitinib results in adverse events (AEs) rates in the postoperative setting that are similar to that with biologic therapy among patients with ulcerative colitis (UC) undergoing colectomy, a study has shown.

Mass vaccination with a recombinant zoster vaccine (RZV) may decrease the burden of herpes zoster (HZ) or shingles in older adults in Singapore (SG), a study suggests.

Adding isatuximab to bortezomib, lenalidomide, and dexamethasone (VRd) regimen provides a significant progression-free survival (PFS) benefit in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible to undergo transplantation compared with VRd alone, according to a prespecified interim analysis of the phase III IMROZ trial presented at EHA 2024.

Patients who filled an opioid prescription following an ophthalmic surgery have higher likelihood of mortality, hospitalization, opioid overdose, and opioid dependence than those who did not fill a prescription, reports a study.